Bristol-Myers Squibb Company BMY announced extended follow-up data and a pre-specified interim overall survival (OS) analysis of Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone in patients with relapsed or refractory multiple myeloma from the phase III ELOQUENT-2 study.
Follow-up data demonstrated that Empliciti plus Revlimid and the dexamethasone regime led to an improvement in progression-free survival compared to Revlimid alone. A pre-specified interim analysis of OS demonstrated a positive trend favoring the Empliciti combination versus Revlimid monotherapy. However, at the time of the interim analysis of the OS endpoint, the pre-determined threshold for statistical significance was not met.
We remind investors that late last month, Empliciti in combination with Revlimid and dexamethasone, for the treatment of multiple myeloma patients who have received one to three prior therapies, was approved by the FDA. Empliciti, an investigational signaling lymphocyte activation molecule (SLAMF7)-directed immunostimulatory antibody, is the first and only one of its kind to be approved for the treatment of multiple myeloma.
Empliciti is also under review in the EU as a combination therapy for the treatment of multiple myeloma patients who have received one or more prior therapies. It has been granted accelerated assessment by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
We note that while Bristol-Myers and AbbVie Inc. ABBV are co-developing Empliciti, with the former having solely undertaken its commercial responsibility.
Both Bristol-Myers and AbbVie currently carry a Zacks Rank #3 (Hold). Baxalta Incorporated BXLT and Gilead Sciences Inc. GILD are a couple of better-ranked stocks in the health care sector. While Baxalta sports a Zacks Rank #1 (Strong Buy), Gilead has a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment